CAMBRIDGE, Mass. and EXTON, Pa, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) (“Idera” or the “Company”) today announced that it intends to offer and sell up to $60 ...

Small-Cap Star Idera Pharmaceuticals (IDRA) popped on Thursday, climbing almost 11 percent on extremely heavy volume. Shares opened close to even, starting up 1.1 percent to $2.75 a share. However, ...

Lately, the stock market has turned on every word from the Federal Reserve, and so this morning's comments from Federal Reserve Chairwoman Janet Yellen received a huge amount of attention from ...

Stock in Idera Pharmaceuticals tanked this week when Celgene announced that the FDA approved Otezla (apremilast) for psoriatic arthritis, a major competitor of Idera's Phase II candidate, IMO-8400.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. The purchase of 5.3 million shares for $3.75 each by ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Idera Pharmaceuticals Inc. has brought in $9.5 million from ...

* Idera Pharmaceuticals Inc - ‍intends to offer and sell up to $60 million of shares of its common stock in an underwritten public offering * Idera - intends to use net proceeds from offering, ...